US Sanctions and Blockade Drive Medicine Costs Beyond Reach for Iranian Patients

Medical care is becoming an increasingly unaffordable commodity in Iran, where the combined weight of American economic sanctions and an effective blockade has sent the price of medicines climbing sharply. A new report from France 24 highlights how the squeeze on Iran's financial and trading systems is being felt most acutely at the pharmacy counter, where patients are confronting costs that have risen far beyond the reach of ordinary households.

The price surge is not the result of a single policy or a sudden shock, but rather the cumulative effect of years of restrictions that have progressively severed Iran from international banking networks, shipping routes and supply chains. Medicines, which are nominally exempt from many sanctions regimes on humanitarian grounds, have nonetheless become collateral damage as banks and logistics firms refuse to handle transactions linked to Iran for fear of running afoul of US penalties.

Iranian patients now face a stark arithmetic: the same prescription that might once have been affordable now consumes a far larger share of a monthly income. For those managing chronic conditions such as diabetes, cancer or cardiovascular disease, the choice between treatment and other basic necessities has become a recurring and painful dilemma. Health professionals warn that when medication becomes a luxury rather than a right, the consequences ripple outward across society, from lost productivity to preventable deaths.

The broader economic context has magnified the problem. Iran has struggled for years with high inflation, a depreciating currency and constrained access to foreign exchange. Sanctions have limited the country's ability to sell oil on global markets, cutting off a vital source of hard currency. Without sufficient foreign reserves, importers find it harder to pay for raw materials and finished pharmaceutical products, and the resulting scarcity pushes prices upward in local currency terms even before any markup at the distribution level.

The US blockade, as described in the France 24 report, refers to the constellation of measures that effectively block Iran from participating in normal international commerce. These include sanctions on banks, restrictions on shipping and insurance, and secondary sanctions that threaten any third-country company or financial institution that does business with Iran. The result is a kind of private-sector embargo that operates alongside official government sanctions, with companies self-censoring to protect their access to the far larger US market.

Humanitarian exemptions exist on paper but often fail in practice. Banks and logistics providers are frequently unwilling to test the boundaries of sanctions rules, because the penalties for a misstep can be severe and the compliance burden is heavy. Even when a transaction is technically permitted, the paperwork and legal risk can be enough to deter participation. The net effect is that food and medicine, which are supposed to be spared, are often caught in the same net as other goods.

Pharmaceutical companies inside Iran have attempted to fill the gap by ramping up domestic production, but they remain dependent on imported active ingredients and specialized equipment. When those imports are disrupted, domestic manufacturers cannot simply substitute local alternatives overnight. Building a fully self-sufficient pharmaceutical supply chain would require years of investment and access to technology that sanctions make difficult to obtain.

Patients and their families describe a daily struggle that has become more desperate as prices climb. Some report skipping doses to stretch a supply, a practice that can lead to complications and emergency hospital visits that are themselves costly. Others turn to informal markets or cross-border purchases, exposing themselves to risks of counterfeit or substandard medicines. The informal trade that emerges in response to scarcity is rarely safe, and it can undermine confidence in the health system as a whole.

International humanitarian organizations have repeatedly called for carve-outs that would allow medicine and medical equipment to flow without hindrance. They argue that sanctions should target governments and specific actors, not the general population, and that the current architecture of restrictions is failing to make that distinction in practice. The debate echoes similar arguments made in other sanctioned contexts, where the humanitarian cost of broad economic pressure has drawn criticism from human rights groups and public health experts.

The Iranian government has pointed to the medicine crisis as evidence that sanctions amount to collective punishment. Officials argue that the United States is using economic pressure to provoke domestic discontent and weaken the state, with ordinary citizens bearing the brunt. Washington, for its part, has maintained that its measures are aimed at specific behavior and that humanitarian goods are exempt, while acknowledging that enforcement and compliance dynamics can complicate the delivery of aid and medical supplies.

Economists note that sanctions rarely change a government's strategic calculus quickly, and that prolonged pressure can entrench hardship without producing the political outcomes intended. In Iran, the combination of sanctions, mismanagement and global economic headwinds has produced a situation where even basic needs are increasingly difficult to meet. Analysts also point out that the current blockade-like environment affects not only prices but the quality of care, as hospitals face shortages of equipment and spare parts.

For patients, the stakes are deeply personal. A cancer patient who cannot afford a course of treatment, a child with a chronic illness whose medication runs out, a diabetic whose insulin supply is uncertain — these are the human faces of a policy debate that often unfolds in abstract terms. Health workers describe moral distress as they counsel families who must choose between essentials, knowing that the clinical consequences of delayed or skipped treatment can be irreversible.

The France 24 report, though brief, points to a wider story about how economic warfare interacts with public health. It suggests that even when humanitarian exemptions are written into sanctions law, the practical reality of enforcement, risk aversion and logistics can transform them into hollow promises. The medicine aisle in Iran has become a barometer of that disconnect, with prices rising and availability shrinking as the broader confrontation plays out.

Looking ahead, the situation is unlikely to improve without either a change in the sanctions landscape or a significant restructuring of Iran's ability to source and produce medicines independently. Neither prospect appears imminent. In the meantime, patients and families continue to absorb the costs, both financial and physical, of a policy environment in which the most vulnerable are often the least protected.

The international community faces a familiar question: how to apply pressure on a government without punishing its people. The Iranian medicine crisis offers a case study in the difficulty of that balance, and a reminder that sanctions are not merely diplomatic tools but forces that shape the daily lives of millions. For now, the pharmacy counter remains one of the most revealing places to observe the human cost of geopolitics.